# Time to leave Fiebig staging in the dust?

Estimated Dates of Detectable Infection (EDDIs) as a new and improved method for HIV infection dating

Shelley N. Facente, PhD, MPH Eduard Grebe, PhD Christopher D. Pilcher, MD, MPH Michael P. Busch, MD, PhD Gary Murphy, PhD Gareth Priede Reshma Kassanjee, PhD Alex Welte, PhD 2022 Advancing HIV, STI and Viral Hepatitis Testing Conference













### Disclosures

Drs. Facente, Grebe, and Busch have received research support from Sedia Biosciences Corporation. Drs. Facente and Grebe have received consulting support and research funding from Gilead Sciences, and through the CDC-funded TRACE program, as a subcontract from the University of California, San Francisco.

These companies and programs had no input into nor influence over the current work.



# Why is Fiebig staging outdated?

- Since this method was published in 2003, HIV testing technology has evolved substantially. Table 1. Laboratory stages of primary HIV infection based on the emergence of viral markers in 51 ser
  - Fiebig stages were defined using estimated length of time it takes for each of 5 assays to have a reactive result after infection.

Table 1. Laboratory stages of primary HIV infection based on the emergence of viral markers in 51 seroconverting plasma donors.

			Marker					
		D D D	Antibody (EIA)		Western -	Duration in days (95% CI) <sup>a</sup>		
Stage	RNA	Antigen	NS	S	blot	Individual	Cumulative	
I	+	_	_	_	_	5.0 (3.1, 8.1)	5.0 (3.1, 8.1)	
11	+	+	_	_	_	5.3 (3.7, 7.7)	10.3 (7.1, 13.5)	
	+	+	_	+	_	3.2 (2.1, 4.8)	13.5 (10.0, 17.0)	
IV	+	+/-	_	+	I	5.6 (3.8, 8.1)	19.1 (15.3, 22.9)	
V	+	+/-	+/-	+	+ <sup>b</sup>	69.5 (39.7, 121.7)	88.6 (47.4, 129.8)	
VI	+	+/-	+	+	+	Open-ended	Open-ended	

<sup>a</sup>Calculations are based on a parametric Markov model.

<sup>b</sup>Without p31 band.

CI, Confidence interval; I, indeterminate; NS, not sensitive, refers to second-generation not IgM-sensitive enzyme immunoassay (EIA); S, sensitive, refers to IgM-sensitive third-generation EIA.

• Today, 3/5 of the assays used for these estimates are no longer in wide use.

# Why is Fiebig staging outdated?

- Fiebig stages can only be assigned to people who have discordant test results.
  - Useful for distinguishing people with acute or early infection (partial seroconversion) vs. someone who's fully seroconverted, but not for infection dating with any precision (especially after seroconversion).

• It is common to employ Fiebig staging loosely, i.e., to assign stages to a particular individual based on the classes of tests rather than the particular tests used in diagnosis.

• It is common to employ Fiebig staging loosely, i.e., to assign stages to a particular individual based on the classes of tests rather than the particular tests used in diagnosis.

March 31, 2022 UniGold RT - Negative Aptima Qual RNA - Reactive

• It is common to employ Fiebig staging loosely, i.e., to assign stages to a particular individual based on the classes of tests rather than the particular tests used in diagnosis.

March 31, 2022 UniGold RT - Negative Aptima Qual RNA - Reactive

Class of test: 3rd gen (IgM-sensitive) NAAT

 It is common to employ Fiebig staging loosely, i.e., to assign stages to a particular individual based on the classes of tests rather than the particular tests used in diagnosis.

March 31, 2022 UniGold RT - Negative Aptima Qual RNA - Reactive

Class of test:3rd gen (IgM-sensitive)NAATFiebig equivalent:Abbott IgM-sensitive EIARoche Amplicor DT50

 It is common to employ Fiebig staging loosely, i.e., to assign stages to a particular individual based on the classes of tests rather than the particular tests used in diagnosis.

#### March 31, 2022 UniGold RT - Negative Aptima Qual RNA - Reactive

Class of test: Fiebig equivalent: Diagnostic delay: (window period) *3rd gen (IgM-sensitive)* Abbott IgM-sensitive EIA 16.7 days

*NAAT* Roche Amplicor DT50 <u>4.85 days</u>

 It is common to employ Fiebig staging loosely, i.e., to assign stages to a particular individual based on the classes of tests rather than the particular tests used in diagnosis.

#### March 31, 2022 UniGold RT - Negative Aptima Qual RNA - Reactive

Class of test:3rd gen (IgM-sensitive)NAATFiebig equivalent:Abbott IgM-sensitive EIARoche Amplicor DT50Fiebig stage I-IIDiagnostic delay:16.7 days4.85 days

 It is common to employ Fiebig staging loosely, i.e., to assign stages to a particular individual based on the classes of tests rather than the particular tests used in diagnosis.

#### March 31, 2022 UniGold RT - Negative Aptima Qual RNA - Reactive

Class of test:3rd gen (IgM-sensitive)NAATFiebig calculationFiebig equivalent:Abbott IgM-sensitive EIARoche Amplicor DT50Fiebig stage I-II16.2 days from inf.Diagnostic delay:16.7 days4.85 days

 It is common to employ Fiebig staging loosely, i.e., to assign stages to a particular individual based on the classes of tests rather than the particular tests used in diagnosis.

#### March 31, 2022 UniGold RT - Negative Aptima Qual RNA - Reactive

Class of test:3rd gen (IgM-sensitive)NAATFiebig calculationFiebig equivalent:Abbott IgM-sensitive EIARoche Amplicor DT50Fiebig stage I-II16.2 days from inf.Diagnostic delay:16.7 days4.85 daysMarch 14, 2022

 It is common to employ Fiebig staging loosely, i.e., to assign stages to a particular individual based on the classes of tests rather than the particular tests used in diagnosis.

25.1 days 4.22 days Diagnostic delay: March 31, 2022 **UniGold RT - Negative Aptima Qual RNA - Reactive** *Class of test:* 3rd gen (IgM-sensitive) NAAT Fiebig calculation *Fiebig equivalent:* Abbott IgM-sensitive EIA Roche Amplicor DT50 Fiebig stage I-II 16.2 days from inf. 4.85 days Diagnostic delay: 16.7 days March 14, 2022

251 dave

Diagnostic delaw

 It is common to employ Fiebig staging loosely, i.e., to assign stages to a particular individual based on the classes of tests rather than the particular tests used in diagnosis.

1 22 dave

Adjusted calculation

Diagnostic delay.	25.1 uays	4.22 Udys		22.9 udys 110111 iiii.
March 31, 2022	<b>UniGold RT - Negative</b>	Aptima Qual RNA - Reactive		
Class of test:	3rd gen (IgM-sensitive)	NAAT		Fiebig calculation
Fiebig equivalent:	Abbott IgM-sensitive EIA	Roche Amplicor DT50	Fiebig stage I-II	16.2 days from inf.
Diagnostic delay:	16.7 days	4.85 days		March 14, 2022

 It is common to employ Fiebig staging loosely, i.e., to assign stages to a particular individual based on the classes of tests rather than the particular tests used in diagnosis.

Adjusted calculation

			Adjusted calculation
25.1 days	4.22 days		22.9 days from inf.
<b>UniGold RT - Negative</b>	Aptima Qual RNA - Reactive		March 8, 2022
3rd gen (IgM-sensitive)	NAAT		Fiebig calculation
Abbott IgM-sensitive EIA	Roche Amplicor DT50	Fiebig stage I-II	16.2 days from inf.
16.7 days	4.85 days		March 14, 2022
	UniGold RT - Negative <i>3rd gen (IgM-sensitive)</i> Abbott IgM-sensitive EIA	UniGold RT - NegativeAptima Qual RNA - Reactive3rd gen (IgM-sensitive)NAATAbbott IgM-sensitive EIARoche Amplicor DT50	UniGold RT - NegativeAptima Qual RNA - Reactive3rd gen (IgM-sensitive)NAATAbbott IgM-sensitive EIARoche Amplicor DT50Fiebig stage I-II

### More importantly

- The Fiebig staging system only provides meaningful information in cases where a person presents with discordant test results on a single day, indicating incomplete seroconversion.
  - i.e., during Fiebig stages I-IV.
- Most individuals present to clinics or research studies after already reaching Fiebig stage V.
  - Then you know nothing, except that they've fully seroconverted already.
  - This is true even if there is a recent negative result.



### What is an "EDDI"?


- EDDI stands for "Estimated Date of Detectable Infection"
- This method uses an individual's testing history to generate a plausible interval of calendar days during which earliest detection by a specified reference test (by default, a viral load assay with a detection threshold of 1 copy/mL) would have occurred.
  - Any reference test could be chosen, it doesn't have to be that default.
- This interval is bounded by the Earliest Plausible Date of Detectable Infection (EP-DDI) and Latest Plausible Date of Detectable Infection (LP-DDI). The midpoint of this "DDI interval" serves as the point estimate, or EDDI.
- Only requirement (other than testing history) is information on the relative "diagnostic delays" of assays in their history.
  - Masciotra et al. J Clin Virol Dec 2011; Delaney et al. CID Jan 2017; Pilcher et al. AIDS 2019
  - Diagnostic delays need to be calibrated to whatever reference test is chosen.


#### Diagnostic Testing History

Test Date	Adjusted Date	Test Name	Test Estimate	Test Result
Dec. 10, 2012	Nov. 30, 2012	ARCHITECT	CDC calc adjusted	Negative
Dec. 10, 2012	Dec. 2, 2012	bDNA	DT formula	Negative
Dec. 12, 2012	Dec. 5, 2012	AptimaPool10	DT formula	Negative
Jan. 10, 2013	Dec. 31, 2012	ARCHITECT	CDC calc adjusted	Positive
Jan. 15, 2013	Jan. 5, 2013	ARCHITECT	CDC calc adjusted	Positive
Jan. 24, 2013	Jan. 16, 2013	bDNA	DT formula	Positive
Jan. 24, 2013	Dec. 27, 2012	WB Full	CDC calc adjusted	Positive
Jan. 24, 2013	Jan. 14, 2013	ARCHITECT	CDC calc adjusted	Positive
March 26, 2013	March 18, 2013	bDNA	DT formula	Positive
April 23, 2013	April 15, 2013	bDNA	DT formula	Positive














- Upload a .csv or .xslx file with 4 columns
  - Long format
  - Call tests whatever you want (you'll map them the first time)
  - Results are always positive or negative

	File	Home	Insert	Draw	Page Layout	Formulas	Data	Review
	\$ \$ \$	Paste	ג נ≞ ∽ ∛	Calibri B I	• <u>∪</u> •   <u>∓</u> •	1 → A^   <u> </u>	A <sup>×</sup>   ≡ •   ≡	I I I I I I I I I I I I I I I I I I I
	Undo	Clipbo	ard 🛛	il	Font		آيا الاتا	Alig
	F9	~		/ <i>fx</i>				
		<b>\</b>	B		С		ν	E
$\mathbf{Q}$	1 Subje	ect Date	e -	Test			Result	
2	2 Subje	ect A 1/1	0/2017	AptimaQa			Positive	
	3 Subje	ect A 1/10	0/2017	GeeniusIn	determinate		Negative	
4	4 Subje	ect B 9/13	3/2016	UnigoldRT	•		Negative	
	5 <mark>Subj</mark> e	ect B 2/4	4/2017	UnigoldRT	•		Positive	
(	6 Subje	ect B 2/4	4/2017	GeeniusFu	ıll		Positive	
	7 Subje	ect C 10/4	4/2004	OraQuick	RT-Blood		Negative	
8	8 <mark>Subj</mark> e	ect C 11/	5/2005	CoulterP2	4		Negative	
9	9 Subje	ect C 5/3	0/2010	Genscreer	וV2		Negative	
1	0 Subje	ect C 9/12	2/2014	AmplicorP	ooledx10		Positive	
1	1 Subje	ect C 9/12	2/2014	BioRadWe	esternBlotIndet	erminate	Negative	
1	2 Subje	ect C 9/24	4/2014	ARCHITEC	Т		Positive	
1	3 Subje	ect C 9/24	4/2014	BioRadWe	esternBlotIndet	erminate	Positive	
1	4 Subje	ect C 9/24	4/2004	BioRadWe	esternBlotFull		Negative	
1	5 Subje	ect C 10/4	4/2014	BioRadWe	esternBlotFull		Positive	
1	6							

Validate Mapping

**Return to data files** 

#### • Then you proceed to mapping (saves within your profile)

Testing Histories Map	ping Tests Residual Risk Help		Logou
Mapping for ExampleData_ lease complete any maps w			
Code	Test	Property	
WesternBlotFull	BioRad GS HIV-1 Western blot Fully Reactive	CEPHIA Estimate	Edit
PoCRT	Trinity Biotech Unigold Rapid HIV Test	CEPHIA Estimate	Edit
WesternBlotIndet	BioRad GS HIV-1 Western blot Indeterminate	CEPHIA Estimate	Edit
QualitativeVL	Aptima HIV-1 RNA Qualitative Assay	CEPHIA Estimate	Edit

- The *Tests* tab lets you view and edit options for each test (connected to your profile, not the global database)
- You can also add your own tests, if you like
- The *Edit* button shows you more detail, and you can add info

#### Global tests

Western blot	
BioRad GS HIV-1 Western blot Fully Reactive	Edit
BioRad GS HIV-1 Western blot Indeterminate	Edit
1st Gen Lab Assay (Viral Lysate IgG sensitive Antibody)	
Murex ICE HIV-1.O.2 EIA	Edit
Unspecified 1st Gen Lab Assay	Edit
bioMerieux Vironostika HIV-1 microelisa EIA	Edit
2nd Gen Lab Assay (Recombinant IgG sensitive Antibody)	
Avioq HIV-1 Microelisa system	Edit
Multispot HIV-1/HIV-2 Rapid Test	Edit
Unspecified 2nd Gen Lab Assay	Edit

Unspecified p24	Antigen						Edit
Vironostika HIV-	Edit Test					×	Edit
4th Gen Lab Assa	Test						
Abbott ARCHITE	Name						Edit
	Abbott ARCHITECT H	HIV Ag/Ab Combo					
Abbott AxSYM H	Category						Edit
BioPlex 2200 HI	4th Gen Lab Assay (p	24 Ag/Ab Combo)				~	Edit
BioRad GS HIV C	Test property estin	nates					Edit
BioRad Genscree	System default estimat	tes are shown in red					Edit
Roche Elecsys HI	Estimate label	VL threshold (copies/ml)	Diagnostic delay p.e. (days)	Diagnostic delay sigma (days)	Comment		Edit
Unspecified 4th C	CEPHIA Estimate		10.8		Delaney- K.P et al. (2017)		Edit
Unspecified 4th C					CID- 64(1):53-59		Edit

• Once mapping is complete, a *Process* button appears.

Festing Histo	ories Mapping	Tests Residual	l Risk Help		Logou
These are ye	our results for: Exa	ampleData2_cPC3	35L4		Download Results
Subject	EP DDI	LP DDI	DDI Interval	EDDI	Flags
Subject A	Dec. 16, 2016	Jan. 6, 2017	21	Dec. 26, 2016	All tests reported are on same date EP-DDI & LP-DDI based on median diagnostic delays Subject has a discordant test date
Subject B	Aug. 19, 2016	Jan. 6, 2017	140	Oct. 28, 2016	EP-DDI & LP-DDI based on median diagnostic delays
Subject C	Aug. 28, 2014	Sept. 4, 2014	7	Aug. 31, 2014	EP-DDI & LP-DDI based on median diagnostic delays Subject has a discordant test date EPDDI and LPDDI less than 10 days apart



### Bottom line...

- Fiebig staging is familiar, and an easy way to categorize people by evolution of infection.
  - But, it's a 20-year-old system based on technology that is outdated.
- The EDDI system is adaptable, flexible, and useful beyond seroconversion to help estimate someone's infection timing.
  - And there's a free tool to help calculate EDDIs easily!
  - You can still categorize people's infection timing if you choose.
- Just like our technology, it's time to update the way we think about how we use that technology to better understand a patient or research participant's HIV story.

Shelley Facente <a href="mailto:shelley@facenteconsulting.com">shelley@facenteconsulting.com</a>



Acknowledgements Eduard Grebe Alex Welte Gareth Priede

Chris Pilcher Gary Murphy Mike Busch